Ouch: Eliem’s pain drug fails second PhII trial, gets scrapped

In April, Eliem Therapeutics’ lead candidate, ETX-810, failed a Phase II study for diabetic nerve pain, buckling the greater Seattle-based biotech’s stock by over half. At the time, Eliem CEO and president Bob Azelby called the results “unambiguous” in not providing benefit for diabetic nerve pain (DPNP). But Eliem had…

Click here to view original post